Literature DB >> 12064467

Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?

Viviana Bazan1, Manuela Migliavacca, Carla Tubiolo, Marcella Macaluso, Ines Zanna, Simona Corsale, Antonella Amato, Valentina Calò, Gabriella Dardanoni, Vincenza Morello, Mario La Farina, Ida Albanese, Rosa Maria Tomasino, Nicola Gebbia, Antonio Russo.   

Abstract

p53 alterations are considered the most common genetic events in many types of neoplasms, including colorectal carcinoma (CRC). These alterations include mutations of the gene and/or overexpression of the protein. The aim of our study was to assess whether in 160 patients undergoing resective surgery for primary operable CRC there was an association between p53 mutations and protein overexpression and between these and other biological variables, such as cell DNA content (DNA-ploidy) and S-phase fraction (SPF), and the traditional clinicopathological variables. p53 mutations, identified by PCR-SSCP-sequencing analysis, were found in 68/160 patients (43%) and positive staining for p53 protein, detected with the monoclonal antibody DO-7, was present in 48% (77/160) of the cases, with agreement of 57% (91/160). In particular, a significant association was found between increased p53 expression and genetic alterations localized in the conserved regions of the gene or in the L3 DNA-binding domain and the specific type of mutation. Furthermore, both overexpression of p53 and mutations in the conserved areas of the gene were found more frequently in distal than in proximal CRCs, suggesting that they might be "biologically different diseases." Although p53 mutations in conserved areas were associated with flow cytometric variables, overexpression of p53 and mutations in its L3 domain were only related respectively to DNA-aneuploidy and high SPF. These data may reflect the complex involvement of p53 in the different pathways regulating cell-cycle progression. In conclusion, the combination of the mutational status and immunohistochemistry of p53, and flow cytometric data may provide an important insight into the biological features of CRCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12064467     DOI: 10.1002/jcp.10088

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

1.  p53 expression in colorectal carcinoma in relation to histopathological features in Ugandan patients.

Authors:  Peter F Rambau; Michael Odida; Henry Wabinga
Journal:  Afr Health Sci       Date:  2008-12       Impact factor: 0.927

2.  Can the clinical outcome in stage II colon carcinomas be predicted by determination of molecular marker expression?

Authors:  J M Fernández-Cebrián; M Nevado Santos; P Vorwald Kuborn; M Pardo de Lama; J Martín-Cavanna; P Pacheco Martínez; B Fernández Escudero; M Ramos Fernández
Journal:  Clin Transl Oncol       Date:  2007-10       Impact factor: 3.405

3.  p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis.

Authors:  E Lopez-Crapez; F Bibeau; S Thézenas; M Ychou; J Simony-Lafontaine; A Thirion; D Azria; J Grenier; P Senesse
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

Review 4.  P53 abnormalities and outcomes in colorectal cancer: a systematic review.

Authors:  A J Munro; S Lain; D P Lane
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

5.  Characterization and Prognostic Value of Mutations in Exons 5 and 6 of the p53 Gene in Patients with Colorectal Cancers in Central Iran.

Authors:  Rahim Golmohammadi; Mohammad J Namazi; Mehdi Nikbakht; Mohammad Salehi; Mohammad H Derakhshan
Journal:  Gut Liver       Date:  2013-04-09       Impact factor: 4.519

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.